Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, and Bihua Chen filed a joint Form 4 on November 2, 2026, disclosing the sale of 425,000 shares of Corbus Pharmaceuticals Holdings, Inc. common stock on October 29, 2026.

Key Highlights

  • Transaction date: 425,000 shares of common stock were disposed of on October 29, 2026.
  • Weighted average price: The reported sale price was $4.1006 per share, representing a weighted average across open market transactions ranging from $4.10 to $4.27 per share.
  • Shares sold by: According to the filing, all shares reported were sold by Cormorant Global Healthcare Master Fund, LP (the "Master Fund").
  • Remaining beneficial ownership: Following the transaction, 1,919,971 shares of common stock are reported as indirectly beneficially owned.
  • Reporting persons: Three reporting persons are named: Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; and Bihua Chen, each classified as "Other" in their relationship to the issuer.
  • Disclaimer: Each reporting person disclaims beneficial ownership of the shares except to the extent of its or her pecuniary interest, and the filing is stated not to be an admission of beneficial ownership for Section 16(a) purposes.

Cormorant Entities Reduce Corbus Pharmaceuticals Position in October 2026 Open Market Sales

According to the Form 4 filed with the SEC on November 2, 2026, Cormorant Asset Management, LP, together with Cormorant Global Healthcare Master Fund, LP and Bihua Chen, reported a sale of 425,000 shares of common stock in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) on October 29, 2026. The transaction code reported is "S," indicating an open market sale. The filing states that all shares were sold by the Master Fund in a series of open market transactions.

The weighted average sale price was reported as $4.1006 per share, with individual transaction prices ranging from $4.10 to $4.27 per share. The filing notes that the reporting persons will provide full information regarding the number of shares sold at each price upon request by SEC staff, the issuer, or a security holder. Following the reported transaction, 1,919,971 shares of common stock remain indirectly beneficially owned, as reported in the filing.

The filing identifies the structural relationships among the reporting persons: Cormorant Asset Management, LP serves as investment manager of the Master Fund; Cormorant Global Healthcare GP, LLC serves as general partner of the Master Fund; and Bihua Chen serves as managing member of Cormorant Asset Management, LP, Cormorant Global Healthcare GP, LLC, and the Master Fund. All three reporting persons are listed under the "Other" category in their relationship to the issuer, with none identified as a director, officer, or current 10% owner.

What Was Disclosed

The filing discloses an open market sale of 425,000 shares of Corbus Pharmaceuticals Holdings, Inc. common stock on October 29, 2026, at a weighted average price of $4.1006, leaving 1,919,971 shares indirectly beneficially owned by the reporting persons following the transaction.